Although molecular analysis for c-kit, PDGFRA mutations, and NF1 status could not be performed in our patient due to logistic constraints, such genetic characterization is increasingly recognized as essential in guiding the choice of tyrosine kinase inhibitors and in tailoring future therapeutic strategies for pediatric GIST. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.